United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Bristol-Myers

Merck

AbbVie, Merck, Bristol Myers Squibb, and Pfizer are the latest beneficiaries of the "Buffett Effect." The quartet of pharmaceutical stocks jumped in pre-market trading on Tuesday after Warren Buffett's Berkshire Hathaway revealed on Monday that it invested in them last quarter. AbbVie, Merck, and Pfizer gained as much as 2%, and BMS rose as much as 3%, whereas benchmark S&P futures slid around 0.5%.

AbbVie, Merck, and Pfizer shares jump after Warren Buffett's Berkshire Hathaway reveals it bought them last quarter

BioNTech SE

As vaccine hype fades, Pfizer and BioNTech are on the cusp of a breakout -- but will they suceed?

2 Top Coronavirus Stocks to Watch in November

Pfizer's vaccine candidate is on the path to being first to market. But one element may keep it from becoming a market leader.

This 1 Factor May Limit the Reach of Pfizer's Coronavirus Vaccine

Warren Buffett is ditching bank stocks and loading up on drug makers, according to Berkshire Hathaway's latest regulatory filing. The post Buffett's Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks appeared first on InvestorPlace.

Buffett's Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks

Pfizer Inc said on Monday it was starting a pilot program for COVID-19 immunization in four U.S. states to help refine the plan for the delivery and deployment of its vaccine candidate.

Pfizer to start pilot program for COVID-19 immunization in four U.S. states

Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) Chairman Warren Buffett has invested in four large drugmakers as the world faces yet another wave of the raging COVID-19 pandemic. What Happened: Regulatory filings made with the United States Securities and Exchange Commission reveal that the legendary investor picked up shares worth nearly $136 million in drugmaker Pfizer Inc (NYSE: PFE) in the latest quarter.

Warren Buffett's Berkshire Bets On These Four Drugmakers Amid Pandemic

The Oracle of Omaha and his team opened new positions in the underperforming sector.

Warren Buffett Bought 4 Pharma Giants in Q3

Snowflake

T-Mobile US

Warren Buffett (Trades, Portfolio)'s $545.8 billion conglomerate, Berkshire Hathaway Inc. (NYSE:BRK.A)(NYSE:BRK.B), disclosed its equity portfolio for the third quarter of 2020 on Monday.

Warren Buffett Buys 6 Stocks in 3rd Quarter, Dumps Costco

Warren Buffett's Berkshire Hathaway is making a big bet on the health care sector at a time when the Covid-19 pandemic continues to be a major crisis in the United States.

Warren Buffett's Berkshire Hathaway makes big bets on drug stocks

Warren Buffett's Berkshire Hathaway invested in AbbVie, Bristol-Myers Squibb, Merck, and Pfizer in the third quarter. The billionaire investor's company disclosed the new holdings in a regulatory filing on Monday. Berkshire boasted stakes worth more than $1.8 billion in each of AbbVie, Bristol Myers Squibb, and Merck as of September 30. It also owned $136 million of Pfizer stock. Buffett and his team also trimmed their Apple stake, which is easily the most valuable holding in their stock portfolio. Visit Business Insider's homepage for more stories. Warren Buffett's Berkshire Hathaway plowed billions of dollars into Pfizer, Merck, and other pharmaceutical stocks in the third quarter, a regulatory filing revealed on Monday.

Warren Buffett's Berkshire Hathaway reveals stakes in AbbVie, Merck, Pfizer, and other 'big pharma' stocks

Warren Buffett's Berkshire Hathaway Inc said on Monday it has begun investing in four large drugmakers.

Buffett's Berkshire invests in several big drugmakers

Citigroup

JPMorgan Chase & Co

SPDR S&P Bank ETF

Wells Fargo

Thanks to favorable Covid-19 vaccine developments, the stage is set for bank stocks to rebound in a big way in 2021. The post 5 Bank Stocks to Buy for the Covid-19 Vaccine Recovery appeared first on InvestorPlace.

5 Bank Stocks to Buy for the Covid-19 Vaccine Recovery

Shares in Pfizer fell on Monday after rival drugmaker Moderna said its experimental vaccine against COVID-19 was 94.5% effective and that it can be stored at normal fridge temperatures.

Pfizer shares drop as Moderna vaccine seen easier to distribute

Novavax

Investors are worried that Moderna's good news could be bad news for these coronavirus vaccine leaders.

Why Pfizer, BioNTech, and Novavax Stocks Are Sinking Today

Moderna

Early data has indicated Pfizer's vaccine could be up to 90% effective and Moderna's could be more than 94% effective.

Former FDA Commissioner Says Pandemic Could ‘Effectively End In 2021' If Pfizer, Moderna Vaccines Live Up To Early Data

The public health leader stressed the need to continue other methods of disease control, like contact tracing, isolating infected patients and testing.

WHO Chief Warns Vaccine Won't End Covid-19 Pandemic As Moderna, Pfizer Announce Early Successes

HHS Secretary Alex Azar said Monday that the FDA will move "as quickly as possible" to issue an authorization for Covid-19 vaccines from Pfizer and Moderna.

HHS Secretary Azar says the FDA will move 'as quickly as possible' to clear Moderna and Pfizer's Covid vaccines

AstraZeneca

Another round of strong COVID-19 vaccine data, this time from Moderna, has put pressure on pharmaceutical companies developing their own vaccine, namely Pfizer, BioNTech, and AstraZeneca. On Monday, Moderna said its late-stage trial evaluating a COVID-19 vaccine candidate demonstrated efficacy of 94.5%, putting the company on track to receive emergency use authorization from the FDA by the end of this year.

Pfizer and AstraZeneca slide as Moderna's rival COVID-19 vaccine shows strong efficacy

Shares of BioNTech SE dropped 5.9% in premarket trading Monday, and Pfizer Inc.'s stock fell 1.7%, after Moderna Inc. said its COVID-19 vaccine candidate can be stored at standard refrigerator temperatures for 30 days, while BioNTech's and Pfizer's vaccine needed to be stored at "ultra-low" temperatures. In addition, Moderna's candidate demonstrated an efficacy rate that may be higher than the BioNTech's and Pfizer's vaccine candidate.

BioNTech, Pfizer stocks fall after upbeat news on Moderna's COVID-19 vaccine candidate

Pfizer's (PFE) vaccine announcement caused euphoria in the market, but sober second thoughts are now setting in.

Pfizer (PFE) and the Headline Effect

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, “We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction. I want to express my gratitude to our Upjohn colleagues for their dedicati

Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan

The Editor-in-Chief of the British medical journal The Lancet explains why Pfizer and Moderna's approach is revolutionary.

Coronavirus Expert on mRNA Vaccines Versus The Old Fashioned Approach

Professor Ugur Sahin, co-founder and chief executive of BioNTech, also suggested the coronavirus vaccine could halve transmission of the virus.

The creator of the Pfizer-BioNTech vaccine says life could return to normal by next winter

BeiGene

Calliditas Therapeutics AB

I-Mab

Thermo Fisher Scientific

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid $2.75 billion to acquire VelosBio, a company formed in 2017 to develop ROR1 ADCs for cancer.

Week In Review: RemeGen, A Yantai Biologics Company, Completes $515 Million Hong Kong IPO

Emirates said it was working with Pfizer on the complex logistics of transporting its vaccine to the world.

News for Pfizer Stock (PFE)